Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal study

• Main Authors: Sebastien Salas, Sophie Mercier, Benjamin Moheng, Sandrine Olivet, Marie-Eve Garcia, Sophie Hamon, Camille Sibertin-Blanc, Florence Duffaud, Pascal Auquier, Karine Baumstarck
• Format: Article
• Language: English
• Published: BMC 2017-04-01
• Series: Health and Quality of Life Outcomes
• Subjects: Nutrition; Cancer; Chemotherapy; Quality-of-life
• Online Access: http://link.springer.com/article/10.1186/s12955-017-0660-6

Abstract Background The aims of this study were to report nutritional status in a large panel of patients with cancer requiring exclusive chemotherapy and to study the influence of nutritional status on their quality of life (QoL). Methods This work was a longitudinal cohort study performed at a French university teaching hospital. Eligible patients were individuals with a cancer needing treatment based on exclusive chemotherapy. Three work-ups were performed: i) before the administration of the first course of chemotherapy: T1, ii) before the administration of the second (for patients with 3 planned courses) or third (patients with 6 planned courses) course: T2, and iii) before the administration of the last planned course: T3. The following data were collected: general health (performance status) and nutritional status (weight, anorexia grading, albuminemia, pre-albuminemia, and C-reactive protein) and QoL. Results The nutritional status of patients with cancer was preserved. Functional impairment, the presence of anorexia, the palliative nature of the chemotherapy, and an elevated C-reactive protein dosage were independent predictive factors of a lower QoL among patients assessed at the end of chemotherapy. Conclusions Although larger studies should corroborate these findings, clinicians may include this information in the management of patients with cancer requiring exclusive chemotherapy to identify the most vulnerable patients. Trial registration Current controlled trials NCT01687335 (registration date: October 6, 2011).